Search This Blog

Thursday, March 26, 2026

Wave Life Sciences to advance obesity candidate WVE-007 to Phase 2a in 2Q

 

Wave Life Sciences to advance obesity candidate WVE-007 to Phase 2a in 2Q 2026 after positive 6-month Phase 1 data

  • Six-month interim Phase 1 INLIGHT results show significant visceral fat reduction and muscle preservation after a single WVE-007 dose.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)